T Cell Engineering

Progress in Tumor Research

Volumn 42, Issue , 2015, Pages 110-135

  Pircher, Magdalena ^a   Schirrmann, Thomas ^b   Petrausch, Ulf ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL ENGINEERING; EXTRACELLULAR SPACE; GENE TRANSFER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT NEOPLASM; NONHUMAN; PRECLINICAL STUDY; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; CYTOLOGY; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; TRANSPLANTATION;

ANIMALS; ANTIGENS, NEOPLASM; CELL ENGINEERING; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84965084264     PISSN: 22961895     EISSN: 22961887     Source Type: Book Series    
DOI: 10.1159/000437180     Document Type: Article

References (158)

1. Scott AM, Wolchok JD, Old LJ: Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-287.
2. Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
3. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001;2:293-299.
4. Smyth MJ, Dunn GP, Schreiber RD: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006;90:1-50.
5. Perez P, Hoffman RW, Shaw S, Bluestone JA, et al. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985;316:354-356.
6. Canevari S, Stoter G, Arienti F, Bolis G, et al. Regression of advanced ovarian-carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995;87:1463-1469.
7. Jain RK: Physiological barriers to delivery of monoclonal-antibodies and other macromolecules in tumors. Cancer Res 1990;50:S814-S819.
8. Blankvoorthuis CJAC, Braakman E, Ronteltap CPM, Tilly BC, et al. Clustered CD3 TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T-lymphocytes via CD3. J Immunol 1993;151:2904-2914.
9. Kipriyanov SM, Cochlovius B, Schafer HJ, Moldenhauer G, et al. Synergistic antitumor effect of bispecific CD19 × CD3 and CD19 × CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J Immunol 2002;169:137-144.
10. Bargou R, Leo E, Zugmaier G, Klinger M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-977.
11. Topp MS, Gokbuget N, Zugmaier G, Degenhard E, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185-5187.
12. Topp MS, Kufer P, Gokbuget N, Goebeler M, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-2498.
13. Eshhar Z, Bach N, Fitzer-Attas CJ, Gross G, et al. The T-body approach: potential for cancer immunotherapy. Springer Semin Immunopathol 1996;18:199-209.
14. Restifo NP, Dudley ME, Rosenberg SA: Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269-281.
15. Hombach AA, Holzinger A, Abken H: The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells. Curr Mol Med 2013;13:1079-1088.
16. Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-Cell receptor-derived C regions. Biochem Biophys Res Commun 1987;149:960-968.
17. Goverman J, Gomez SM, Segesman KD, Hunkapiller T, et al. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell 1990;60:929-939.
18. Roberts MR, Qin L, Zhang D, Smith DH, et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 1994;84:2878-2889.
19. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4:132ra53.
20. Nolan KF, Yun CO, Akamatsu Y, Murphy JC, et al. Bypassing immunization: optimized design of 'designer T cells' against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999;5:3928-3941.
21. Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, et al. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2000;2:449-459.
22. Bird RE, Hardman KD, Jacobson JW, Johnson S, et al. Single-chain antigen-binding proteins. Science 1988;242:423-426.
23. Asano R, Takemura S, Tsumoto K, Sakurai N, et al. Functional construction of the anti-mucin core protein (MUC1) antibody MUSE11 variable regions in a bacterial expression system. J Biochem (Tokyo) 2000;127:673-679.
24. Gilham DE, Debets R, Pule M, Hawkins RE, et al. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 2012;18:377-384.
25. Eshhar Z, Fitzer-Attas CJ: Tyrosine kinase chimeras for antigen-selective T-body therapy. Adv Drug Deliv Rev 1998;31:171-182.
26. Zenner G, Vorherr T, Mustelin T, Burn P: Differential and multiple binding of signal transducing molecules to the ITAMs of the TCR-ζ chain. J Cell Biochem 1996;63:94-103.
27. Shores E, Flamand V, Tran T, Grinberg A, et al. FcϵRI γ can support T cell development and function in mice lacking endogenous TCR ζ-chain. J Immunol 1997;159:222-230.
28. Haynes NM, Snook MB, Trapani JA, Cerruti L, et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs FcϵRI-γ. J Immunol 2001;166:182-187.
29. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24:e20-e22.
30. Kershaw MH, Westwood JA, Parker LL, Wang G, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-6115.
31. Finney HM, Lawson AD, Bebbington CR, Weir AN: Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998;161:2791-2797.
32. Finney HM, Akbar AN, Lawson AD: Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J Immunol 2004;172:104-113.
33. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, et al. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 2005;105:3087-3093.
34. Hombach A, Sent D, Schneider C, Heuser C, et al. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res 2001;61:1976-1982.
35. Krause A, Guo HF, Latouche JB, Tan C, et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998;188:619-626.
36. Alvarez-Vallina L, Hawkins RE: Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 1996;26:2304-2309.
37. Haynes NM, Trapani JA, Teng MW, Jackson JT, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002;169:5780-5786.
38. Haynes NM, Trapani JA, Teng MW, Jackson JT, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002;100:3155-3163.
39. Ren-Heidenreich L, Mordini R, Hayman GT, Siebenlist R, et al. Comparison of the TCR ζ-chain with the FcR γ-chain in chimeric TCR constructs for T cell activation and apoptosis. Cancer Immunol Immunother 2002;51:417-423.
40. Kofler DM, Chmielewski M, Rappl G, Hombach A, et al. CD28 costimulation impairs the efficacy of a redirected T-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing Lck activation. Mol Ther 2011;19:760-767.
41. Gramaglia I, Weinberg AD, Lemon M, Croft M: Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998;161:6510-6517.
42. Rogers PR, Song J, Gramaglia I, Killeen N, et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001;15:445-455.
43. Pule MA, Straathof KC, Dotti G, Heslop HE, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005;12:933-941.
44. Till BG, Jensen MC, Wang J, Qian X, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012;119:3940-3950.
45. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009;183:5563-5574.
46. Kalos M, Levine BL, Porter DL, Katz S, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
47. Porter DL, Levine BL, Kalos M, Bagg A, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-733.
48. Kloss CC, Condomines M, Cartellieri M, Bachmann M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013;31:71-75.
49. Hanada K, Restifo NP: Double or nothing on cancer immunotherapy. Nat Biotechnol 2013;31:33-34.
50. Willemsen RA, Debets R, Chames P, Bolhuis RL: Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 2003;64:56-68.
51. Fcreceptor ζ chain. Cell 1992;68:889-897.
52. Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z: Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J Immunol 1998;160:145-154.
53. McGuinness RP, Ge Y, Patel SD, Kashmiri SV, et al. Anti-tumor activity of human T cells expressing the CC49-ζ chimeric immune receptor. Hum Gene Ther 1999;10:165-173.
54. Kolanus W, Romeo C, Seed B: T cell activation by clustered tyrosine kinases. Cell 1993;74:171-183.
55. Eshhar Z, Waks T, Gross G, Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993;90:720-724.
56. Patel SD, Moskalenko M, Smith D, Maske B, et al. Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther 1999;6:412-419.
57. Moritz D, Groner B: A spacer region between the single chain antibody-and the CD3 ζ-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 1995;2:539-546.
58. +leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res 2005;29:301-306.
59. Schuberth PC, Jakka G, Jensen SM, Wadle A, et al. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther 2013;20:386-395.
60. Hombach A, Sircar R, Heuser C, Tillmann T, et al. Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and γ or ζ signalling chains. Int J Mol Med 1998;2:99-103.
61. Hombach A, Hombach AA, Abken H: Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther 2010;17:1206-1213.
62. Ren Heidenreich L, Hayman GT, Trevor KT: Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors. Hum Gene Ther 2000;11:9-19.
63. Eshhar Z, Waks T, Bendavid A, Schindler DG: Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001;248:67-76.
64. Stewart-Jones G, Wadle A, Hombach A, Shenderov E, et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A 2009;106:5784-5788.
65. Finer MH, Dull TJ, Qin L, Farson D, et al. kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994;83:43-50.
66. Weijtens ME, Willemsen RA, Hart EH, Bolhuis RL: A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther 1998;5:1195-1203.
67. Engels B, Cam H, Schuler T, Indraccolo S, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther 2003;14:1155-1168.
68. Gladow M, Becker C, Blankenstein T, Uckert W: MLV-10A1 retrovirus pseudotype efficiently transduces primary human CD4+ T lymphocytes. J Gene Med 2000;2:409-415.
69. Stitz J, Buchholz CJ, Engelstadter M, Uckert W, et al. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 2000;273:16-20.
70. Uckert W, Becker C, Gladow M, Klein D, et al. Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype. Hum Gene Ther 2000;11:1005-1014.
71. Altenschmidt U, Klundt E, Groner B: Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J Immunol 1997;159:5509-5515.
72. Altenschmidt U, Kahl R, Moritz D, Schnierle BS, et al. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 1996;2:1001-1008.
73. Bester AC, Schwartz M, Schmidt M, Garrigue A, et al. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther 2006;13:1057-1059.
74. Williams DA, Baum C: Gene therapy-new challenges ahead. Science 2003;302:400-401.
75. Baum C, Dullmann J, Li Z, Fehse B, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003;101:2099-2114.
76. Gattinoni L, Lugli E, Ji Y, Pos Z, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17:1290-1297.
77. Durand S, Cimarelli A: The inside out of lentiviral vectors. Viruses 2011;3:132-159.
78. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science Transl Med 2012;4:132ra53.
79. Jensen MC, Clarke P, Tan G, Wright C, et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther 2000;1:49-55.
80. Jensen MC, Cooper LJ, Wu AM, Forman SJ, et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 2003;5:131-138.
81. Maiti SN, Huls H, Singh H, Dawson M, et al. Sleeping Beauty system to redirect T-cell specificity for human applications. J Immunother 2013;36:112-123.
82. Rongvaux A, Willinger T, Martinek J, Strowig T, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 2014;32:364-372.
83. Yuan S, Ziman A, Smeltzer B, Lu Q, et al. Moderate and severe adverse events associated with apheresis donations: incidences and risk factors. Transfusion 2010;50:478-486.
84. Winters JL: Complications of donor apheresis. J Clin Apher 2006;21:132-141.
85. Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, et al. Clinical-scale selection and viral transduction of human naive and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol Immunother 2013;62:1563-1573.
86. Kaiser AD, Assenmacher M, Schroder B, Meyer M, et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther 2015;22:72-78.
87. Bajgain P, Mucharla R, Anurathapan U, Lapteva N, et al. A novel approach to manufacture CAR-T cells for clinical applications. Biol Blood Marrow Transplant 2013;19:S194-S195.
88. Jakka G, Schuberth PC, Thiel M, Held G, et al. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system. Anticancer Res 2013;33:4189-4201.
89. Ertl HC, Zaia J, Rosenberg SA, June CH, et al. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res 2011;71:3175-3181.
90. Till BG, Jensen MC, Wang J, Chen EY, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112:2261-2271.
91. Savoldo B, Ramos CA, Liu E, Mims MP, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011;121:1822-1826.
92. Brentjens RJ, Riviere I, Park JH, Davila ML, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817-4828.
93. Brentjens R, Yeh R, Bernal Y, Riviere I, et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010;18:666-668.
94. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709-2720.
95. Maude SL, Frey N, Shaw PA, Aplenc R, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-1517.
96. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517-528.
97. Bolhuis RL, Willemsen RA, Lamers CH, Stam K, et al. Preparation for a phase I/II study using autologous gene modified T lymphocytes for treatment of metastatic renal cancer patients. Adv Exp Med Biol 1998;451:547-555.
98. Lamers CH, Gratama JW, Pouw NM, Langeveld SC, et al. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression. Hum Gene Ther 2005;16:1452-1462.
99. Parente-Pereira AC, Burnet J, Ellison D, Foster J, et al. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J Clin Immunol 2011;31:710-718.
100. Lamers CH, Willemsen R, van Elzakker P, van Steenbergen-Langeveld S, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011;117:72-82.
101. Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013;21:904-912.
102. Park JR, Digiusto DL, Slovak M, Wright C, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15:825-833.
103. Morgan RA, Yang JC, Kitano M, Dudley ME, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-851.
104. Ahmed N, Brawley VS, Hegde M, Robertson C, et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 2015;33:1688-1696.
105. Beatty GL, Haas AR, Maus MV, Torigian DA, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014;2:112-120.
106. Schumacher TN, Schreiber RD: Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
107. Mihara K, Yanagihara K, Takigahira M, Imai C, et al. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. J Immunother 2009;32:737-743.
108. Mihara K, Bhattacharyya J, Kitanaka A, Yanagihara K, et al. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia 2012;26:365-367.
109. Brentjens RJ, Latouche JB, Santos E, Marti F, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003;9:279-286.
110. Cooper LJN, Topp MS, Serrano LM, Gonzalez S, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003;101:1637-1644.
111. Schmidt P, Kopecky C, Hombach A, Zigrino P, et al. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A 2011;108:2474-2479.
112. Wang J, Press OW, Lindgren CG, Greenberg P, et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther 2004;9:577-586.
113. James ST, Greenberg PD, Jensen MC, Lin YK, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol 2008;180:7028-7038.
114. Hombach A, Heuser C, Sircar R, Tillmann T, et al. An anti-CD30 chimeric receptor that mediates CD3-ζ-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res 1998;58:1116-1119.
115. Savoldo B, Rooney CM, Di Stasi A, Abken H, et al. Epstein Barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007;110:2620-2630.
116. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010;116:4532-4541.
117. Chmielewski M, Hombach A, Heuser C, Adams GP, et al. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 2004;173:7647-7653.
118. Muniappan A, Banapour B, Lebkowski J, Talib S: Ligand-mediated cytolysis of tumor cells: use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther 2000;7:128-134.
119. Ren-Heidenreich L, Hayman GT, Trevor KT: Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors. Hum Gene Ther 2000;11:9-19.
120. Daly T, Royal RE, Kershaw MH, Treisman J, et al. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther 2000;7:284-291.
121. Zhang T, Lemoi BA, Sentman CL: Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 2005;106:1544-1551.
122. Weijtens ME, Willemsen RA, Valerio D, Stam K, et al. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 1996;157:836-843.
123. D2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 2001;94:228-236.
124. Abken H, Hombach A, Heuser C, Reinhold U: A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T cells with tumor specificity. Recent Results Cancer Res 2001;158:249-264.
125. Gonzalez S, Naranjo A, Serrano LM, Chang WC, et al. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. J Gene Med 2004;6:704-711.
126. Morgenroth A, Cartellieri M, Schmitz M, Gunes S, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007;67:1121-1131.
127. Hwu P, Yang JC, Cowherd R, Treisman J, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995;55:3369-3373.
128. Kershaw MH, Westwood JA, Hwu P: Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002;20:1221-1227.
129. Hekele A, Dall P, Moritz D, Wels W, et al. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:ζ-chimera. Int J Cancer 1996;68:232-238.
130. Dall P, Herrmann I, Durst B, Stoff-Khalili MA, et al. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells. Cancer Immunol Immunother 2005;54:51-60.
131. Pameijer CR, Navanjo A, Meechoovet B, Wagner JR, et al. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther 2007;14:91-97.
132. Gilham DE, O'Neil A, Hughes C, Guest RD, et al. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3ζ-based chimeric immune receptors. J Immunother 2002;25:139-151.
133. Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, et al. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci U S A 2002;99:7009-7014.
134. Gattenlohner S, Marx A, Markfort B, Pscherer S, et al. Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor. Cancer Res 2006;66:24-28.
135. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007;13:5426-5435.
136. Loskog A, Giandomenico V, Rossig C, Pule M, et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006;20:1819-1828.
137. Vera J, Savoldo B, Vigouroux S, Biagi E, et al. T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006;108:3890-3897.
138. Di Stasi A, De Angelis B, Rooney CM, Zhang L, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009;113:6392-6402.
139. Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv Hematol 2012;2012:683065.
140. Thokala R, Olivares S, Singh H, Champlin RE, Cooper LJN: Targeting leukemia by CD123 specific chimeric antigen receptor. Biol Blood Marrow Transplant 2012;18:S291.
141. Pinthus JH, Waks T, Malina V, Kaufman-Francis K, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004;114:1774-1781.
142. Davies DM, Foster J, van der Stegen SJC, Parente-Pereira AC, et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med 2012;18:565-576.
143. Haynes NM, Trapani JA, Teng MW, Jackson JT, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002;169:5780-5786.
144. Maher J, Brentjens RJ, Gunset G, Riviere I, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol 2002;20:70-75.
145. Zhang T, Wu MR, Sentman CL: An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J Immunol 2012;189:2290-2299.
146. Kong S, Sengupta S, Tyler B, Bais AJ, et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 2012;18:5949-5960.
147. Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, et al. Successful eradication of established peritoneal ovarian tumors in SCID-beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res 2010;16:3594-3606.
148. D2is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer 2012;106:1123-1133.
149. Westwood JA, Smyth MJ, Teng MW, Moeller M, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A 2005;102:19051-19056.
150. Willemsen RA, Ronteltap C, Chames P, Debets R, et al. T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005;174:7853-7858.
151. Cheung NK, Guo HF, Modak S, Cheung IY: Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy. Hybrid Hybridomics 2003;22:209-218.
152. Kochenderfer JN, Feldman SA, Zhao YB, Xu H, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 2009;32:689-702.
153. Marin V, Pizzitola I, Agostoni V, Attianese GMPG, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 2010;95:2144-2152.
154. Morgan RA, Johnson LA, Davis JL, Zheng Z, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012;23:1043-1053.
155. Carpenito C, Milone MC, Hassan R, Simonet JC, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009;106:3360-3365.
156. Zhong XS, Matsushita M, Plotkin J, Riviere I, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 2010;18:413-420.
157. Wilkie S, Picco G, Foster J, Davies DM, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 2008;180:4901-4909.
158. Geldres C, Savoldo B, Hoyos V, Caruana I, et al. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res 2014;20:962-971.